Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 3, 2011, Pages 245-250

  Wu, Meina ^a   Wang, Yuyan ^a   An, Tongtong ^a   Zhao, Jun ^a   Yang, Lu ^a   Duan, Jianchun ^a   Wang, Zhijie ^a   Zhuo, Minglei ^a   Bai, Hua ^a   Liu, Xuyi ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Female; Lung neoplams; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SYMPTOM; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79953192556     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.03.21     Document Type: Article

References (17)

1. Fu JB, Kau TY, Severson RK, et al. Lung cancer in women:analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 2005, 127(3): 768-777.
2. Yang GH. Prevalence levels, trends and distribution of death and its risk factors in Chinese population. Beijing: Peking Union Medical College Press, 2005. 75. [(Chinese Source), 2005. 75.]
3. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Ann Oncol, 2002, 13(7): 1087-1093.
4. Paesmans M, Sculier JP, Libert G. Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin oncol, 1995, 13(5): 1221-1230.
5. O'Connel, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-smallcell lung cancer treated with combination chemotherapy. J Clin Oncol, 1986, 4(11): 1604-1614.
6. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in nonsmall cell lung cancer survival. An analysis of 4618 patients diagnosed between 1997 and 2002. Ann Thorac Surg, 2004, 78(1): 209-215.
7. Wakelee HA, Wang W, Shiller JH, et al. Survival deifferences by sex for patients with advanced non-small-cell lung cancer on Eastern Cooperative Oncology Group Trial 1594. J Thorac Oncol, 2006, 1(5): 441-446.
8. Bai H, Mao L, Wang SH, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol, 2009, 27(16): 2663-2669.
9. Shepherd FA, Pereira PR, Ciuleanu T, et al. Erlotinib in previously treatednon-small-cell lung ancer. N Engl J Med, 2005, 353(2): 123-132.
10. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinnib for previously treated patients with advanced non-smallcell lung cancer. J Clin Oncol, 2003, 21(12): 2237-2246.
11. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA, 2003, 290(16): 2149-2158.
12. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
13. Guillermo PJ, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
14. Wang SH, An TT, Wang J, et al. Potential clinical significance of a plasmabased KRAS mutation analysis in patients with advanced NSCLC. Clin Cancer Res, 2010, 16(4): 1324-1330.
15. Zhu CQ, Santos GC, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008, 26(26): 4268-4275.
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol, 2006, 24(31): 5034-5042.
17. Weiss GJ, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol, 2007, 18(3): 453-460.